Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent

International Journal of Pharmaceutics

Volumn 482, Issue 1-2, 2015, Pages 2-10

  Lozano, Neus ^a   Al Ahmady, Zahraa S ^a   Beziere, Nicolas S ^b   Ntziachristos, Vasilis ^b   Kostarelos, Kostas ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cancer nanotechnology; Nanomedicine; Optical imaging; Photoacoustics; Targeting

Indexed keywords

DOXORUBICIN; INDOCYANINE GREEN; LIPOSOME; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; MACROGOL DERIVATIVE; MUC-1 MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER MODEL; CANCER SIZE; COLON ADENOCARCINOMA; DRUG ACCUMULATION; DRUG DISTRIBUTION; ENCAPSULATION; HUMAN; HUMAN CELL; MOUSE; MULTI SPECTRAL OPTOACOUSTIC TOMOGRAPHY; NONHUMAN; PHOTOACOUSTIC TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE; IMMUNOLOGY; METABOLISM; NEOPLASM; PHOTOACOUSTICS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CONTRAST MEDIA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENCE; HUMANS; INDOCYANINE GREEN; LIPOSOMES; MICE; NEOPLASMS; PHOTOACOUSTIC TECHNIQUES; POLYETHYLENE GLYCOLS;

EID: 84923871245     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.10.045     Document Type: Article

References (51)

1. Z.S. Al-Ahmady, O. Chaloin, and K. Kostarelos Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia J. Controlled Release 2014 10.1016/j.jconrel.2014.10.013
2. W.T. Al-Jamal, Z.S. Al-Ahmady, and K. Kostarelos Pharmacokinetics and tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia Biomaterials 33 2012 4608 4617
3. W.T. Al-Jamal, and K. Kostarelos Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine Acc. Chem. Res. 44 2011 1094 1104
4. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763
5. A.D. Bangham, and R.W. Horne Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J. Mol. Biol. 8 1964 660 668
6. C. Bao, N. Beziere, P. del Pino, B. Pelaz, G. Estrada, F. Tian, V. Ntziachristos, J.M. de la Fuente, and D. Cui Gold nanoprisms as optoacoustic signal nanoamplifiers for in vivo bioimaging of gastrointestinal cancers Small 9 2013 68 74
7. Y. Barenholz Doxil(R) - the first FDA-approved nano-drug: lessons learned J. Controlled Release 160 2012 117 134
8. N. Beziere, N. Lozano, A. Nunes, J. Salichs, D. Queiros, K. Kostarelos, and V. Ntziachristos Dynamic Imaging of PEGylated indocyanine green (ICG) liposomes within the tumor microenvironment using multi-spectral optoacoustic tomography (MSOT) Biomaterials 37 2015 415 424
9. A. Buehler, E. Herzog, D. Razansky, and V. Ntziachristos Video rate optoacoustic tomography of mouse kidney perfusion Optics Lett. 35 2010 2475 2477
10. S.Y. Chan, A.N. Gordon, R.E. Coleman, J.B. Hall, M.S. Berger, M.L. Sherman, C.B. Eten, and N.J. Finkler A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma Cancer Immunol. Immunother. 52 2003 243 248
11. C.-W. Chen Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells Int. J. Nanomed. 6 2011 2567 2580
12. Q. Davies, A.C. Perkins, M. Frier, S. Watson, E. Lalani, and E.M. Symonds The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model Eur. J. Nucl. Med. 24 1997 206 209
13. M. de Smet, S. Langereis, S. van den Bosch, K. Bitter, N.M. Hijnen, E. Heijman, and H. Grull SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound J. Controlled Release 169 2013 82 90
14. R. Eitan, A. Fishman, M. Meirovitz, H. Goldenberg, A. Amit, C. Koren, Y. Schneider, O. Rosengarten, A. Neuman, S. Keren-Rosenberg, and T. Safra Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis Anticancer Drugs 25 2014 101 105
15. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 63 2011 136 151
16. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992
17. A. Gabizon, H. Shmeeda, and T. Grenader Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy Eur. J. Pharm. Sci. 45 2012 388 398
18. A. Gabizon, D. Tzemach, J. Gorin, L. Mak, Y. Amitay, H. Shmeeda, and S. Zalipsky Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models Cancer Chemother. Pharmacol. 66 2010 43 52
19. A.M. Gillespie, T.J. Broadhead, S.Y. Chan, J. Owen, A.P. Farnsworth, M. Sopwith, and R.E. Coleman Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer Ann. Oncol. 11 2000 735 741
20. K.J. Harrington, G. Rowlinson-Busza, K.N. Syrigos, R.G. Vile, P.S. Uster, A.M. Peters, and J.S. Stewart Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model Clin. Cancer Res. 6 2000 4939 4949
21. E. Herzog, A. Taruttis, N. Beziere, A.A. Lutich, D. Razansky, and V. Ntziachristos Optical imaging of cancer heterogeneity with multispectral optoacoustic tomography Radiology 263 2012 461 468
22. L.M. Hinman, P.R. Hamann, R. Wallace, A.T. Menendez, F.E. Durr, and J. Upeslacis Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res. 53 1993 3336 3342
23. A.K. Iyer, G. Khaled, J. Fang, and H. Maeda Exploiting the enhanced permeability and retention effect for tumor targeting Drug Disc. Today 11 2006 812 818
24. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
25. H.S. Jeong, C.M. Lee, S.J. Cheong, E.M. Kim, H. Hwang, K.S. Na, S.T. Lim, M.H. Sohn, and H.J. Jeong The effect of mannosylation of liposome-encapsulated indocyanine green on imaging of sentinel lymph node J. Liposome Res. 23 2013 291 297
26. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
27. T. Lammers Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Controlled Release 161 2012 175 187
28. K. Loomis, B. Smith, Y. Feng, H. Garg, A. Yavlovich, R. Campbell-Massa, D.S. Dimitrov, R. Blumenthal, X. Xiao, and A. Puri Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv Exp. Mol. Pathol. 88 2010 238 249
29. D.E. Lopes de Menezes, L.M. Pilarski, and T.M. Allen In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma Cancer Res. 58 1998 3320 3330
30. N. Lozano, W.T. Al-Jamal, A. Taruttis, N. Beziere, N.C. Burton, J. Van den Bossche, M. Mazza, E. Herzog, V. Ntziachristos, and K. Kostarelos Liposome-gold nanorod hybrids for high-resolution visualization deep in tissues J. Am. Chem. Soc. 134 2012 13256 13258
31. A.N. Lukyanov, T.A. Elbayoumi, A.R. Chakilam, and V.P. Torchilin Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody J. Controlled Release 100 2004 135 144
32. H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 88 2012 53 71
33. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Delivery Rev. 65 2013 71 79
34. C. Mamot, D.C. Drummond, C.O. Noble, V. Kallab, Z. Guo, K. Hong, D.B. Kirpotin, and J.W. Park Epidermal growth factor receptor - targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 65 2005 11631 11638
35. A.M. Minisini, C. Andreetta, G. Fasola, and F. Puglisi Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer Expert Rev. Anticancer Ther. 8 2008 331 342
36. J.N. Moreira, T. Ishida, R. Gaspar, and T.M. Allen Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity Pharm. Res. 19 2002 265 269
37. V. Ntziachristos, and D. Razansky Molecular imaging by means of multispectral optoacoustic tomography (MSOT) Chem. Rev. 110 2010 2783 2794
38. J.W. Park, D.B. Kirpotin, K. Hong, R. Shalaby, Y. Shao, U.B. Nielsen, J.D. Marks, D. Papahadjopoulos, and C.C. Benz Tumor targeting using anti-her2 immunoliposomes J. Controlled Release 74 2001 95 113
39. U. Prabhakar, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, and D.C. Blakey Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 73 2013 2412 2417
40. H.M. Prinssen, C.F. Molthoff, R.H. Verheijen, T.J. Broadhead, P. Kenemans, J.C. Roos, Q. Davies, A.C. van Hof, M. Frier, W. den Hollander, A.J. Wilhelm, T.S. Baker, M. Sopwith, E.M. Symonds, and A.C. Perkins Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01 Cancer Immunol. Immunother. 47 1998 39 46
41. S.T. Proulx, P. Luciani, S. Derzsi, M. Rinderknecht, V. Mumprecht, J.C. Leroux, and M. Detmar Quantitative imaging of lymphatic function with liposomal indocyanine green Cancer Res. 70 2010 7053 7062
42. P. Sapra, and T.M. Allen Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs Cancer Res. 62 2002 7190 7194
43. R.R. Sawant, and V.P. Torchilin Liposomes as 'smart' pharmaceutical nanocarriers Soft Matter 6 2010 4026 4044
44. R.A. Schwendener, and H. Schott Liposome formulations of hydrophobic drugs Methods Mol. Biol. 605 2010 129 138
45. S. Sofou, and G. Sgouros Antibody-targeted liposomes in cancer therapy and imaging Expert Opin. Drug Delivery 5 2008 189 204
46. R. Suzuki, T. Takizawa, Y. Kuwata, M. Mutoh, N. Ishiguro, N. Utoguchi, A. Shinohara, M. Eriguchi, H. Yanagie, and K. Maruyama Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome Int. J. Pharm. 346 2008 143 150
47. T. Tejada-Berges, C.O. Granai, M. Gordinier, and W. Gajewski Caelyx/doxil for the treatment of metastatic ovarian and breast cancer Expert Rev. Anticancer Ther. 2 2002 143 150
48. V. Torchilin Antibody-modified liposomes for cancer chemotherapy Expert Opin. Drug Delivery 5 2008 1003 1025
49. F.Y. Yang, H.E. Wang, R.S. Liu, M.C. Teng, J.J. Li, M. Lu, M.C. Wei, and T.T. Wong Pharmacokinetic analysis of 111 in-labeled liposomal doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound PLoS One 7 2012 e45468
50. T. Yang, M.-K. Choi, F.-D. Cui, J.S. Kim, S.-J. Chung, C.-K. Shim, and D.-D. Kim Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome J. Controlled Release 120 2007 169 177
51. Y. Zhuang, Y. Ma, C. Wang, L. Hai, C. Yan, Y. Zhang, F. Liu, and L. Cai PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution J. Controlled Release 159 2012 135 142